Abstract
This report describes a case of biopsy-confirmed EGPA in which early initiation of mepolizumab, guided by biomarker surveillance, resulted in steroid-free MPO-ANCA seroconversion. These findings suggest a potential steroid-sparing strategy for ANCA-positive EGPA.